Skip to content

Edwards Lifesciences

US · EW #442 by market cap Listed 1970
101.85 -2.03 -1.95%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • Company notice
    Edwards Lifesciences | 4: Statement of changes in beneficial ownership of securities-Officer Zovighian Bernard J
    SEC · 2026/11/10
  • Rating change
    BofA Securities Maintains Edwards Lifesciences(EW.US) With Buy Rating
    Market Newswire · 2026/11/10
  • Rating change
    Edwards Lifesciences Is Maintained at Buy by TD Cowen
    Dow Jones · 2026/11/12
  • Rating change
    TD Cowen Maintains Edwards Lifesciences(EW.US) With Buy Rating, Raises Target Price to $121
    Market Newswire · 2026/11/11
  • Rating change
    Edwards Lifesciences Price Target Raised to $121.00/Share From $117.00 by TD Cowen
    Dow Jones · 2026/11/12
  • Rating change
    TD Cowen Initiates Edwards Lifesciences(EW.US) With Buy Rating, Announces Target Price $117
    Market Newswire · 2026/11/10
  • Rating change
    Edwards Lifesciences Is Maintained at Overweight by Wells Fargo
    Dow Jones · 2026/11/16
  • Rating change
    Wells Fargo Maintains Edwards Lifesciences(EW.US) With Buy Rating, Raises Target Price to $121
    Market Newswire · 2026/11/16
  • RBC Capital Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $115
    Market Newswire · 2026/11/20
  • Leerink Partners Adjusts Price Target on Edwards Lifesciences to $116 From $112
    MT Newswires · 2026/11/19
  • Rating change
    Wells Fargo Adjusts Price Target on Edwards Lifesciences to $121 From $113
    MT Newswires · 2026/11/16
  • Company notice
    Edwards Lifesciences | 144: Notice of proposed sale of securities pursuant to Rule 144
    SEC · 2026/11/11
  • Rating change
    Daiwa Securities Adjusts Price Target on Edwards Lifesciences to $120 From $98
    MT Newswires · 2026/11/12
  • Leerink Partners Maintains Edwards Lifesciences(EW.US) With Buy Rating, Raises Target Price to $116
    Market Newswire · 2026/11/19
  • Company notice
    Edwards Lifesciences | 4: Statement of changes in beneficial ownership of securities-Officer Dahl Andrew M.
    SEC · 2026/11/14
  • RBC Capital Maintains Edwards Lifesciences(EW.US) With Buy Rating, Raises Target Price to $115
    Market Newswire · 2026/11/20
  • Edwards Lifesciences' 2027 Guidance Seen Leaving Room for Upward Revisions, RBC Says
    MT Newswires · 2026/11/21
  • Company notice
    Edwards Lifesciences | 8-K: Current report
    SEC · 2026/11/20
  • Rating change
    TD Cowen Adjusts Price Target on Edwards Lifesciences to $121 From $117
    MT Newswires · 2026/11/11
  • Company notice
    Edwards Lifesciences | 4: Statement of changes in beneficial ownership of securities-Officer Lippis Daniel J.
    SEC · 2026/11/11
  • Rating change
    Edwards Lifesciences Is Maintained at Overweight by JP Morgan
    Dow Jones · 2026/11/6
  • Rating change
    Edwards Lifesciences Is Maintained at Overweight by Wells Fargo
    Dow Jones · 2026/11/5
  • Rating change
    Barclays Maintains Overweight on Edwards Lifesciences, Raises Price Target to $120
    Benzinga · 2026/11/6
  • A Quick Look at Today's Ratings for Edwards Lifesciences(EW.US), With a Forecast Between $106 to $125
    Market Newswire · 2026/11/6
  • Citigroup Maintains Buy on Edwards Lifesciences, Raises Price Target to $117
    Benzinga · 2026/11/6

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:29 · For reference only, not investment advice and not tailored to your situation.

Edwards Lifesciences discussion 0 comments

Add a comment